Boehringer Fails to Inform Public of Mirapex Heart Failure Risk
According to a recent report , drugmaker Boehringer Ingelheim failed to completely inform the public about information that suggested the dopamine agonist Mirapex (pramipexole) was linked to an increased risk of heart failure. The drug, which was originally developed to treat Parkinson’s disease, is now used to treat Restless Legs Syndrome as well. Even